Financial Highlights:

• Total sales in the period of £30.8m (FY22: £27.2m)
• Creo core product sales and Kamaptive licensing income in the period of £4.0m (FY22: £2.3m), with 2.5x increase in Creo core product sales of £2.3m (FY22: £0.9m)
• Gross margin up 1.1 ppt to 49.6% (FY22: 48.5%), with gross profit of £15.3m (FY22: £13.2m)
• Reduced operating loss of £24.8m for FY23 (FY22: £30.7m)
• Reduced underlying operating loss* of £16.4m for FY23 (FY22: £20.8m) in-line with market expectations, including £2.8m (FY22: £4.5m) of R&D credits.
• Research and Development expenditure reduced to £11.8m (FY22: £13.5m) of which 2/3rds relates to products in development with the Group’s global partners or work carried out on Speedboat Ultraslim which launched in December 2023.
• £33.7m raised through oversubscribed fundraise in March 2023.
• £17.4m cash as at 31 March 2024.

*underlying operating loss is loss after accounting for share-based payments, depreciation and amortisation, R&D tax credit, earnout and other one-off settlements.

Operational and Commercial Highlights (including post-period end):

• FDA clearance for Speedboat UltraSlim received in November 2023; initial uptake has been very positive
• EU launch of Speedboat UltraSlim accelerated by 18 months, following guidance from notified body – first sales achieved in Q4-23 with exceptional customer feedback and growing orderbook
• Speedboat UltraSlim roll-out reached Asia Pacific and Latin America, with first uses in these regions taking place in December 2023
• Significant progress in roll-out of Creo’s core technology since start of 2023 with 119% increase in user base to 175 (FY22: 80)
• Speedboat Inject selected by the National Institute for Health and Care Excellence ("NICE") to be scoped and routed for guidance

• In March 2023, first in-human use of MicroBlate Flex for the microwave ablation of soft tissue lung lesions safely completed as part of a lung tissue ablation clinical study
  • • In February 2024, a robotic guided microwave ablation of lung tissue in the same sitting as a diagnostic procedure was performed at the Royal Brompton Hospital, with MicroBlate Flex used to perform the procedure.

• Medical Device Regulation CE clearance for Speedboat, adding upper gastrointestinal ("GI") indications (e.g. swallowing disorders, oesophageal and stomach cancers) in the UK and mainland Europe, with multiple upper GI Speedboat procedures performed in Europe during H2-23.
• Most significant data set for Speedboat Submucosal Dissection ("SSD") procedures to date, showing an 82% curative rate for lower GI lesions (e.g. bowel and colon) with no perforations recorded.
• Speedboat Submucosal Dissection (“SSD”) service at Royal Oldham immediately implemented following training, with multiple cases completed in record time, resulting in immediate benefits for both patients and waiting lists.
• NHS Supply Chain data announced in April 2024 demonstrated significant cost and operational savings provided by the use of SSD procedures.
• Collaboration with Khalifa University of Science & Technology, Abu Dhabi announced post-year end.
• Increased global reach, with first use of Speedboat in Croatia, Slovenia, Malaysia and UAE.

FY24 Update and Outlook

Q1-24 trading has been in-line with expectations following the approvals for UltraSlim at the turn of the year. Following a strong finish in Q4-23, sales momentum in Creo core products has continued with core revenue in Q1-24 showing a 14% increase over the FY23 quarterly average, and the Company expects to see this accelerate in Q2-24, driven by anticipated strong sales of Speedboat UltraSlim and building on the strong performance in Q4-23. Consumable sales were impacted by the early Easter compared to Q4-23, but the Group remains on track for H1-24 targets.  Tight control on costs has been maintained, ensuring that the Group’s operating expenses, to date, remain on budget. This, together with the continuing sales momentum, gives the Board confidence that the Group will achieve its 2024 objectives for core revenue and deliver on the potential of Creo's technology.